Acta Med. 2023, 66: 117-121

https://doi.org/10.14712/18059694.2024.4

Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting

David Garridoa, Virginia Boveb, Fiorella Villanoc, Eloísa Rivaa

aCátedra de Hematología, Hospital de Clínicas, Av Italia, sn; Montevideo, CP 11600, Uruguay
bHospital Central de las Fuerzas Armadas, Ocho de octubre 3020, CP 11600, Montevideo, Uruguay
cCASMU, Montevideo, Uruguay

Received March 16, 2023
Accepted November 26, 2023

References

1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95(5): 548–67. Erratum in: Am J Hematol 2020; 95(11): 1444. <https://doi.org/10.1002/ajh.25791>
2. Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int 2016; 113(27–28): 470–6.
3. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016; 43(6): 676–81. <https://doi.org/10.1053/j.seminoncol.2016.11.004> <PubMed>
4. Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J 2019; 9(4): 44. <https://doi.org/10.1038/s41408-019-0205-9> <PubMed>
5. Attal M, Lauwers-Cances V, Hulin C, et al. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood 2015; 126(23): 391. <https://doi.org/10.1182/blood.V126.23.391.391>
6. O’Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-center experience in 211 patients. Bone Marrow Transplant 2006; 37(8): 731–7. <https://doi.org/10.1038/sj.bmt.1705307>
7. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15(12): e538–e548.5 <https://doi.org/10.1016/S1470-2045(14)70442-5>
8. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 2020; 7(6): e456–e468. Erratum in: Lancet Haematol 2020; 7(6): e443. Erratum in: Lancet Haematol 2020; 7(11): e785. <https://doi.org/10.1016/S2352-3026(20)30099-5>
9. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022; 387(2): 132–47. <https://doi.org/10.1056/NEJMoa2204925> <PubMed>
10. Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. Blood Cancer J 2018; 8(12): 123. <https://doi.org/10.1038/s41408-018-0155-7> <PubMed>
11. Paquin AR, Kumar SK, Buadi FK, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on the outcome. Blood Cancer J 2018; 8(12): 125. <https://doi.org/10.1038/s41408-018-0163-7> <PubMed>
12. Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J 2022; 12(1): 21. <https://doi.org/10.1038/s41408-022-00611-x> <PubMed>
13. D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol 2022; 40(29): 3406–18. <https://doi.org/10.1200/JCO.21.02614>
14. Perrot A, Lauwers-Cances V, Tournay E, et al. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. J Clin Oncol 2019; 37(19): 1657–65. <https://doi.org/10.1200/JCO.18.00776> <PubMed>
15. Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood 2019; 133(11): 1217–21. <https://doi.org/10.1182/blood-2018-10-880831> <PubMed>
16. Corre J, Perrot A, Caillot D, et al. Del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood 2021; 137(9): 1192–5. <https://doi.org/10.1182/blood.2020008346> <PubMed>
17. Stong N, Ortiz Estevez M, Towfic F, et al. Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients. Blood 2023; 141(13): 1574–83. <https://doi.org/10.1182/blood.2022016212> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive